IP Library Granted Patent US 8,188,220
Granted Patent B2
US 8,188,220 · App. 11/951,819 · Granted May 29, 2012

Methods and compositions related to targeting wounds, regenerating tissue, and tumors

Assignee: Sanford-Burnham Medical Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,188,220
App. No.
11/951,819
Granted
May 29, 2012
Kind
B2
Abstract

Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.

Claims (74)

1. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 1 having one or two conservative amino acid substitutions, or the amino acid sequence of SEQ ID NO: 2 having three or more conservative amino acid substitutions.

2. The isolated peptide of claim 1 , wherein the amino acid sequence of SEQ ID NO: 1 has two conservative amino acid substitutions, wherein the amino acid sequence of SEQ ID NO: 2 has three conservative amino acid substitutions.

3. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 1, wherein the peptide has a length of less than 100 residues.

4. The isolated peptide of claim 1 , wherein the peptide has a length of less than 50 residues.

5. The isolated peptide of claim 1 , wherein the peptide has a length of less than 20 residues.

6. The isolated peptide of claim 1 , wherein the amino acid segment is cyclic.

7. The isolated peptide of claim 6 , wherein the amino acid segment is cyclicized via a disulfide bond.

8. The isolated peptide of claim 1 , wherein the peptide selectively homes to regenerating tissue.

9. The isolated peptide of claim 8 , wherein the regenerating tissue is at a site of injury.

10. The isolated peptide of claim 8 , wherein the regenerating tissue is at a surgical site.

11. The isolated peptide of claim 1 , wherein the peptide selectively homes to a tumor.

12. The isolated peptide of claim 1 , wherein the peptide selectively homes to a site of inflammation.

13. The isolated peptide of claim 1 , wherein the peptide selectively homes to a site of arthritis.

14. The isolated peptide of claim 1 , wherein the peptide consists of the amino acid segment.

15. A conjugate, wherein the conjugate comprises a moiety linked to the peptide of claim 1 .

16. The conjugate of claim 15 , wherein the peptide selectively interacts with regenerating tissue.

17. The conjugate of claim 15 , wherein the peptide selectively interacts with tissue at a site of inflammation.

18. The conjugate of claim 15 , wherein the peptide selectively interacts with tissue at a site of arthritis.

19. The conjugate of claim 15 , wherein the peptide selectively interacts with a tumor.

20. The conjugate of claim 15 , wherein the moiety is a an anti-angiogenic agent, a pro-angiogenic agent, a cancer chemotherapeutic agent, a cytotoxic agent, an anti-inflammatory agent, an anti-arthritic agent, a polypeptide, a nucleic acid molecule, a small molecule, a fluorophore, fluorescein, rhodamine, a radionuclide, indium-111, technetium-99, carbon-11, carbon-13, or a combination.

21. The conjugate of claim 15 , wherein the moiety is a therapeutic agent.

22. The conjugate of claim 21 , wherein the therapeutic agent is decorin.

23. The conjugate of claim 15 , wherein the moiety is a detectable agent.

24. The conjugate of claim 15 , wherein the conjugate comprises a virus.

25. The conjugate of claim 24 , wherein the conjugate comprises a phage.

26. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 having one or more conservative amino acid substitutions, wherein the peptide is fused to at least one heterologous moiety, wherein the moiety is not a polypeptide.

27. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 having one or more conservative amino acid substitutions, wherein the peptide is part of a chimeric protein.

28. An isolated peptide consisting of an amino acid segment, wherein the amino acid segment consists of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 having one or more conservative amino acid substitutions, wherein the peptide has a length of less than 20 residues.

29. An isolated peptide consisting of an amino acid segment, wherein the amino acid segment consists of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

30. An isolated peptide consisting of an amino acid segment consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 having one, two, or three conservative amino acid substitutions.

31. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 2 having one or more conservative amino acid substitutions, wherein the peptide has a length of less than 20 residues.

32. The isolated peptide of claim 31 , wherein the amino acid segment is cyclic.

33. The isolated peptide of claim 32 , wherein the amino acid segment is cyclicized via a disulfide bond.

34. The isolated peptide of claim 31 , wherein the peptide selectively homes to regenerating tissue.

35. The isolated peptide of claim 31 , wherein the peptide selectively homes to a tumor.

36. The isolated peptide of claim 31 , wherein the peptide selectively homes to a site of inflammation.

37. The isolated peptide of claim 31 , wherein the peptide is part of a chimeric protein.

38. The isolated peptide of claim 31 , wherein the peptide consists of the amino acid segment, wherein the amino acid segment consists of the amino acid sequence.

39. A conjugate, wherein the conjugate comprises a moiety linked to the peptide of claim 31 .

40. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 2 having one or more conservative amino acid substitutions, wherein the peptide has a length of less than 100 residues, wherein the amino acid segment is cyclic.

41. The isolated peptide of claim 40 , wherein the amino acid segment is cyclicized via a disulfide bond.

42. The isolated peptide of claim 40 , wherein the peptide selectively homes to regenerating tissue.

43. The isolated peptide of claim 40 , wherein the peptide selectively homes to a tumor.

44. The isolated peptide of claim 40 , wherein the peptide selectively homes to a site of inflammation.

45. The isolated peptide of claim 40 , wherein the peptide is part of a chimeric protein.

46. The isolated peptide of claim 40 , wherein the peptide consists of the amino acid segment, wherein the amino acid segment consists of the amino acid sequence.

47. A conjugate, wherein the conjugate comprises a moiety linked to the peptide of claim 40 .

48. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 2 having one or more conservative amino acid substitutions, wherein the peptide has a length of less than 100 residues, wherein the peptide is part of a chimeric protein.

49. The isolated peptide of claim 48 , wherein the amino acid segment is cyclic.

50. The isolated peptide of claim 49 , wherein the amino acid segment is cyclicized via a disulfide bond.

51. The isolated peptide of claim 48 , wherein the peptide selectively homes to regenerating tissue.

52. The isolated peptide of claim 48 , wherein the peptide selectively homes to a tumor.

53. The isolated peptide of claim 48 , wherein the peptide selectively homes to a site of inflammation.

54. The isolated peptide of claim 48 , wherein the peptide consists of the amino acid segment, wherein the amino acid segment consists of the amino acid sequence.

55. A conjugate, wherein the conjugate comprises a moiety linked to the peptide of claim 48 .

56. A conjugate, wherein the conjugate comprises a moiety linked to a peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 2 having one or more conservative amino acid substitutions, wherein the peptide has a length of less than 100 residues.

57. The conjugate of claim 56 , wherein the peptide selectively interacts with regenerating tissue.

58. The conjugate of claim 56 , wherein the peptide selectively interacts with tissue at a site of inflammation.

59. The conjugate of claim 56 , wherein the peptide selectively interacts with tissue at a site of arthritis.

60. The conjugate of claim 56 , wherein the peptide selectively interacts with a tumor.

61. The conjugate of claim 56 , wherein the moiety is a an anti-angiogenic agent, a pro-angiogenic agent, a cancer chemotherapeutic agent, a cytotoxic agent, an anti-inflammatory agent, an anti-arthritic agent, a polypeptide, a nucleic acid molecule, a small molecule, a fluorophore, fluorescein, rhodamine, a radionuclide, indium-111, technetium-99, carbon-11, carbon-13, or a combination.

62. The conjugate of claim 56 , wherein the moiety is a therapeutic agent.

63. The conjugate of claim 62 , wherein the therapeutic agent is decorin.

64. The conjugate of claim 56 , wherein the moiety is a detectable agent.

65. The conjugate of claim 56 , wherein the conjugate comprises a virus.

66. The conjugate of claim 65 , wherein the conjugate comprises a phage.

67. The isolated peptide of claim 1 , wherein the peptide has a length of less than 100 residues.

68. The isolated peptide of claim 1 , wherein the amino acid sequence of SEQ ID NO: 1 has one conservative amino acid substitution.

69. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 1.

70. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 2, wherein the peptide has a length of less than 70 residues.

71. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence of SEQ ID NO: 1 having one or more conservative amino acid substitutions, wherein the peptide has a length of less than 50 residues.

72. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence of SEQ ID NO: 2 having one or more conservative amino acid substitutions, wherein the peptide has a length of less than 30 residues.

73. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 1 having four or more conservative amino acid substitutions, wherein the peptide has a length of less than 100 residues.

74. An isolated peptide comprising an amino acid segment comprising the amino acid sequence of SEQ ID NO: 2 having two or more conservative amino acid substitutions, wherein the peptide has a length of less than 90 residues.

Assignments (4)
CONFIRMATORY LICENSE Recorded Nov 6, 2023
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: UNITED STATES GOVERNMENT
Reel/Frame 065474/0036 →
CHANGE OF NAME Recorded Oct 8, 2020
From: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
To: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Reel/Frame 054033/0296 →
CHANGE OF NAME Recorded Dec 1, 2010
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 025434/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2008
From: RUOSLAHTI, ERKKI; JARVINEN, TERO
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 021935/0644 →
Continuity (2)
Provisional Application 60868772 · Dec 6, 2006
Related Publication 20090036349A1 · Feb 5, 2009